Neuroendocrine carcinoma of the epiglottis. Case report
Holguin-Estrada EA, Gonzalez-Macouzet J, Avalos-Trejo OA, Lopez-Martinez BA, de Haro-Estrada DA. Neuroendocrine carcinoma of the epiglottis. Case report. Am J Med Surg. 2020 Oct 2(1):23-27.
From the Department of Oncologic Surgery at Hospital General 450, Durango, Mexico. Received on October 14, 2020. Accepted on October 19, 2020. Published on October 21, 2020.
Abstract: Neuroendocrine carcinoma is a rare disease, represent less than 1% of the tumors of the larynx, moderately differentiated neuroendocrine carcinomas are the most common type of laryngeal neuroendocrine carcinoma and due to their relatively higher frequency, the majority of cases occur in male patients with a mean patient age of 61 years (range, 36-83 years). Neuroendocrine carcinomas are classified according to their cellular differentiation into well-differentiated neuroendocrine carcinoma, moderately differentiated neuroendocrine carcinoma, and poorly differentiated neuroendocrine carcinoma. The moderately differentiated neuroendocrine carcinoma tumors present as supraglottic masses in the arytenoids, epiglottis, or aryepiglottic folds, commonly causing hoarseness or dysphagia, It is relatively aggressive and has a greater propensity for regional and distant failure, leading to a worse prognosis. The mainstay of treatment for moderately differentiated carcinoma of the larynx is surgical excision. We present a 41-year-old caucasian female, with 1 year of evolution with a sensation of pharyngeal globus, who presents moderately differentiated neuroendocrine carcinoma, and was treated with conservative management, with good evolution, Treatment is based on resection, polychemotherapy, and concomitant radiation therapy. The prognosis is dire with a 5-year survival rate of 5%.
Keywords: Epiglottis carcinoma, neuroendocrine tumor, neuroendocrine carcinoma.